Engineering the Human Microbiome Shows Promise for Treating Disease
By Justin L. Sonnenburg,
Scientific American
| 02. 17. 2015
Untitled Document
In the not too distant future each of us will be able to colonize our gut with genetically modified “smart” bacteria that detect and stamp out disease at the earliest possible moment. This scenario may sound like the premise for a sci-fi flick, but it is a very real possibility. Microbiome engineering holds great promise because of advances in the field of synthetic biology, which strives to create and rewire biological organisms so they perform desired tasks. Synthetic biologists are attempting to turn bacterial cells into the biological equivalent of the silicon wafer. These principles have been primarily applied to organisms for biofuel production, but the resulting techniques and genetic tool kit, when applied to our resident microbes, will have profound consequences for human health.
These resident microbes are adept at sensing what food is present, whether any pathogens are lurking and what the inflammatory state of the gut is—their survival depends on it. The model gut-resident bacterial species that we are using in our laboratory for initial tests, Bacteroides thetaiotaomicron, possesses more than 100 genetic circuits...
Related Articles
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...
By Antonia O'Flaherty, ABC News Australia | 03.04.2026
Fertility giant Monash IVF has agreed to pay financial settlements to families involved in two major bungles that saw two women transferred the wrong embryo.
In February 2025 the company became aware that one of its Brisbane clinic's patients had...